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Abstract
Alzheimer’s disease (AD) is the leading cause of dementia in the elderly and is characterized
by memory loss and cognitive decline. Pathological hallmark of AD brains are intracellular
neurofibrillary tangles and extracellular amyloid plaques. The major component of these pla-
ques is the highly heterogeneous amyloid-β (Aβ) peptide, varying in length and modification.
In recent years pyroglutamate-modified amyloid-β (pEAβ) peptides have increasingly moved
into the focus since they have been described to be the predominant species of all N-termi-
nally truncated Aβ. Compared to unmodified Aβ, pEAβ is known to show increased hydro-
phobicity, higher toxicity, faster aggregation and β-sheet stabilization and is more resistant to
degradation. Nuclear magnetic resonance (NMR) spectroscopy is a particularly powerful
method to investigate the conformations of pEAβ isoforms in solution and to study peptide/
ligand interactions for drug development. However, biophysical characterization of pEAβ and
comparison to its non-modified variant has so far been seriously hampered by the lack of
highly pure recombinant and isotope-enriched protein. Here we present, to our knowledge,
for the first time a reproducible protocol for the production of pEAβ from a recombinant pre-
cursor expressed in E. coli in natural isotope abundance as well as in uniformly [U-15N]- or
[U-13C, 15N]-labeled form, with yields of up to 15 mg/l E. coli culture broth. The chemical state
of the purified protein was evaluated by RP-HPLC and formation of pyroglutamate was veri-
fied by mass spectroscopy. The recombinant pyroglutamate-modified Aβ peptides showed
characteristic sigmoidal aggregation kinetics as monitored by thioflavin-T assays. The quality
and quantity of produced pEAβ40 and pEAβ42 allowed us to perform heteronuclear multidi-
mensional NMR spectroscopy in solution and to sequence-specifically assign the backbone
resonances under near-physiological conditions. Our results suggest that the presented
method will be useful in obtaining cost-effective high-quality recombinant pEAβ40 and
pEAβ42 for further physiological and biochemical studies.
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Introduction
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive decline
of cognitive functions and has become the main cause for dementia in the elderly [1, 2]. Patho-
logical hallmarks of AD are intracellular neurofibrillary tangles and the accumulation of extra-
cellular amyloid plaques [3, 4]. Amyloid-β (Aβ), the major component of these amyloid
plaques, is produced by cleavage of the amyloid precursor protein through β- and γ-secretases,
generating various Aβ isoforms varying in length [5–9]. Besides Aβ isoforms starting with the
amino acid (aa) D at position 1 (D1), a significant amount of N-terminally truncated Aβ vari-
ants is deposited in the brains of AD patients [10, 11], whereby pyroglutamate (pE)-modified
Aβ species were described as the major isoforms [12–15]. Up to 20% of the total Aβ are
reported to bear a pE residue at the N-terminus [16]. N-terminally truncated pEAβ(3-x) spe-
cies, with the first two N-terminal aa D1 and A2 being absent, are dominant isoforms in AD
brains [17, 18] and are present in up to equivalent amounts compared to full-length Aβ(1-x) in
senile plaques [19–21]. The intracellular amount of pEAβ increases with age and it is predomi-
nantly found in lysosomes of neurons and neuroglia [22]. pEAβ plays a central role in trigger-
ing neurodegeneration and lethal neurological deficits [23, 24]. Thus, N-terminally modified
Aβ isoforms represent highly desirable therapeutic targets and became more important in the
recent years [15, 25–27].
Aβ(3-x) can be generated by the removal of the first two aa (D1 and A2) from Aβ(1-x) or by
alternative splicing, leading to the N-terminal aa E3. The enzyme glutaminyl cyclase (QC) cata-
lyzes intra-E lactam ring formation involving the N-terminal amino group of E3 and its γ-car-
boxyl group by dehydration leading to pEAβ [28, 29]. Although N-terminal pE formation is a
preferred enzymatic reaction [30], it can also be achieved non-enzymatically [31]. This reaction
is accelerated with an N-terminal Q residue as a substrate instead of E [32].
The conversion results in altered biophysical and biochemical properties since: (1) pEAβ
shows higher hydrophobicity due to the formation of the N-terminal pE lactam ring and the
loss of three charges resulting in increased aggregation propensity [12, 19]. (2) The blocked N-
terminus leads to higher stability since it is inaccessible for degradation by aminopeptidases.
(3) pEAβ shows faster aggregation kinetics with up to 250-fold acceleration and (4) is also
more neurotoxic as compared with corresponding non-N-terminally truncated Aβ species
independent of their C-terminal lengths [24, 33–36].
A deeper understanding of the molecular mechanisms of pEAβ formation, aggregation and
its structure may provide new insights into the difference compared to Aβ and its role in AD.
Structural data from NMR spectroscopy could extend the knowledge of pEAβ pathogenicity
and will give information about ligand interactions for rational drug design. However, large
amounts of pEAβ are needed for such studies. Principally, peptides up to 100 amino acid resi-
dues can be prepared chemically by solid phase synthesis, but when it comes to isotope-
enriched peptides this strategy becomes very costly and constant biological activity is not
guaranteed since there are often differences in purity between the batches [37].
Here, we report a method for reproducible expression and purification of recombinant
pEAβ(3–40) and pEAβ(3–42) with natural isotope abundance, as well as uniformly [U-15N] or
[U-13C, 15N]-labeled protein with yields up to 15 mg/l culture based on a previously published
protocol for Aβ by Finder, Glockshuber and coworkers [37]. To avoid time and cost consuming
enzymatic pE formation by QC, we applied conditions for nonenzymatic pE formation on Aβ
(E3Q-x) mutants leading to complete and more rapid pEAβ formation compared to the Aβ
(E3-x) species. The chemical and conformational states of the purified pEAβ proteins were
characterized biophysically by mass spectrometry, thioflavin-T (ThT) assay and solution NMR
spectroscopy.
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Results and Discussion
Cloning, expression and purification of the mutants Aβ(E3Q-40/42)
The fusion constructs Aβ(E3Q-40) and Aβ(E3Q-42) are based on the recombinant Aβ(1–42)
E. coli derived construct published by Finder, Glockshuber and coworkers [37] consisting of a
His6-tag, a solubilizing fusion partner (NANP)19, established previously [38], followed by a
TEV protease recognition and cleavage site and the Aβ sequence 3-40/42. E3 was replaced by
Q in order to improve the non-enzymatic reaction to pE (Method A in S1 File). The protease
recognition site thus is now modified to ENLYFQ#Q, where the arrow indicates the cleavage
site, leading to Q3 as the N-terminal aa in the resulting Aβ constructs. Typically, the TEV pro-
tease recognition and cleavage site contains a G or a S C-terminal of the TEV protease cut, but
as proven previously, an exchange of G or S to Q leads to 90% cleavage efficiency [39]. Thus Q
becomes the first aa (Q3) of the cleavage product, which is readily susceptible to non-enzymatic
pE formation under mild acidic and elevated temperature conditions. To show the applicability
and advantage of this mutation for non-enzymatic pEAβ conversion, we additionally produced
Aβ(3–42) starting at the N-terminal position with the original E instead of Q, which in vivo is
the primary substrate for QC and is catalytically converted to pEAβ but can also be modified
non-enzymatically [28]. We found that Aβ(3–42) converted to pEAβ significantly slower than
Aβ(E3Q-42) with Q at the N-terminal position.
Expression of the fusion constructs in E. coli BL21 (DE3) pLysS was obtained at a high cell
density of OD600nm 1.2. Reducing the temperature after induction to 30°C and expression
overnight resulted in a large amount of fusion protein accumulated in inclusion bodies
(Fig 1a). Denaturing conditions were necessary to solubilize these inclusion bodies. The first
purification step was an IMAC in 8 M GdmCl. One-step washing of the IMAC column with 20
mM imidazole and subsequent elution with 500 mM imidazole was performed to isolate the
fusion protein and to remove most of non-specifically bound impurities as analyzed by analyti-
cal RP-HPLC (Fig 1b). Typical retention time of fusion Aβ(E3Q-40) was 5 min and 7 min for
fusion Aβ(E3Q-42). The fusion proteins were further purified using preparative RP-HPLC and
lyophilized from aqueous ACN resulting in pure fusion protein determined via SDS-PAGE
according to Laemmli [40] (Fig 1c, Method B in S1 File). The following yields per l of cell cul-
ture were obtained as shown in Table 1: 200 ± 5 mg for fusion Aβ(E3Q-40/42) and fusion Aβ
(3–42) in natural abundance, 25 ± 3 mg for [U-15N] fusion Aβ(E3Q-40/42) and 20 ± 3 mg for
[U-13C, 15N] fusion Aβ(E3Q-40/42).
Next, the lyophilized fusion proteins were analyzed for efficient TEV protease cleavage. It
turned out, that high molar ratios of TEV protease were necessary to balance the modified
cleavage site, i.e. ENLYFQ#Q, instead of ENLYFQ#G/S. Enhanced cleavage reaction was
achieved by lowering the incubation temperature to 4°C by decreasing the aggregation of the
cleaved Aβ with remaining fusion protein (Method C in S1 File). Most of the fusion Aβ(E3Q-
40/42) were cleaved within 7 h, as proven by analytical RP-HPLC (Fig 2a and 2b). Retention-
time of cleaved Aβ(E3Q-40) was approximately 8.9 min and 12.2 min for Aβ(E3Q-42). After
overnight incubation, cleaved Aβ(E3Q-42) and Aβ(3–42) precipitated during the reaction
completely, whereas around 50% of Aβ(E3Q-40) stayed in solution. Precipitates were resolved
in 8 M GdmCl for further purification. Chromatograms of preparative HPLC indicate that
there was still some fusion protein remaining (Fig 2c) which could be removed by adjusting the
gradient as described in the Materials and Methods section. Cleaved Aβ was separated from
the fusion-tag and TEV protease and lyophilized. As the fusion-tag accounts for 70% of the
total fusion protein, a maximum of 30 mg target protein per 100 mg fusion protein is theoreti-
cally obtainable with 100% cleavage efficiency. In total, approximately 20 mg purified cleaved
Aβ(E3Q-40/42) per 100 mg fusion protein were received.
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Conversion to pEAβ40 and pEAβ42
It is known, that N-terminal pE formation from E is a preferred enzymatical reaction [30], but
also can be achieved non-enzymatically under mild acidic conditions and increased tempera-
ture [31]. However, both enzymatic and non-enzymatic intra-molecular lactam formation with
an N-terminal Q residue instead of E is much faster [32]. For this reason, we decided to use the
mutant Aβ(E3Q) for spontaneous pE formation and compared it with a construct bearing E3
at the N-terminus. The reaction schemes for the conversion to pE from N-terminal E by dehy-
dration or from N-terminal Q by subtraction of ammonia are shown in Fig 3d. Purified Aβ
(E3Q-40), Aβ(E3Q-42) and Aβ(3–42) were dissolved in acetate buffer at pH 3.5 and incubated
at 45°C for spontaneous pE formation (Method D in S1 File). Reaction was observed with ana-
lytical RP-HPLC at the start of the reaction, after 3 h and after 24 h incubation, respectively
(Fig 3a and 3b). Due to the loss of the positively charged hydrophilic amino group, the pE-
modified peptides get more hydrophobic resulting in a longer retention time on RP-HPLC. For
Aβ(E3Q-40)and Aβ(E3Q-42), the initial peptide peaks eluting at 8.2 or 12.6 min decreased
Fig 1. Expression and purification of fusion Aβ(E3Q-42) protein in E. coli BL21 (DE3) pLysS. (a) 15% Tris/Glycine-SDS-PAGE analysis of the lysates
before IPTG induction (t = 0 h) and after IPTG induction leading to expression of fusion Aβ(E3Q-42) (t = 16 h after induction) at 30°C. (b) Analytical RP-HPLC
of IMAC purified fusion Aβ(E3Q-40) (red) and fusion Aβ(E3Q-42) (black) with typical retention times of 5 and 7 min, respectively. (c) 15% Tris/Glycine-
SDS-PAGE of IMAC and RP-HPLC purified fusion Aβ(E3Q-42).
doi:10.1371/journal.pone.0139710.g001
Table 1. Yields of intermediates and final purified pEAβ peptides in mg per l culture broth.
Natural abundant [mg/l] [U-15N] labeled [mg/l] [U-13C,15N] labeled [mg/l]
fusion Aβ(E3Q-40) 205 28 23
Aβ(E3Q-40) 42 5 4.5
pEAβ40 15 2.3 2
fusion Aβ(E3Q-42) 200 24 20
Aβ(E3Q-42) 41 4.8 4
pEAβ42 14 2.1 1.8
doi:10.1371/journal.pone.0139710.t001
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over time while new peaks eluting at 9.5 or 15 min emerging due to pE conversion of Aβ(E3Q-
40) and Aβ(E3Q-42) appeared. MALDI-mass spectrometry (see below) proved the conversion
to the corresponding pE-modified variants. An incubation time of 24 h was appropriate to con-
vert most of Aβ(E3Q-40/42) to pEAβ40 and pEAβ42, respectively, as observable by RP-HPLC
analytics (Fig 3a and 3b).
Conversion was proven by comparing a non-pE-converted sample of [U-15N]-Aβ(E3Q-40)
with [U-15N]-pEAβ40 using MALDI-mass spectrometry (Fig 3e, Method F in S1 File). The cal-
culated averaged mass of [U-15N]-Aβ(E3Q-40) is 4194 Da and 4176 Da for [U-15N]-pEAβ40.
Major peaks differing in 18 Da mass were visible, which corresponds to the loss of 15NH3.
However, the exact mass of both peptides were 2 Da less than calculated based on the fact that
the purified protein is not monoisotopic, but at least 95% of all nitrogen atoms are 15N isotopes.
Non-enzymatic conversion of Aβ(3–42) containing the N-terminal E3 to pEAβ42 showed a
pronounced decreased efficiency under exactly the same conditions, i.e. 24 h incubation time
at 45°C incubation temperature with sodium acetate, pH 3.5, as buffer condition. Only approx-
imately 55% were non-enzymatically converted to pEAβ42 after 24 h incubation time (Fig 3c).
Although the incubation time was increased up to 3 days, an improvement of the E to pE con-
version was not observable, most likely as a consequence of aggregation. Thus, we proved that
the E3Q mutation facilitates and increases the yield of the final pEAβ significantly.
Since pEAβ precipitated completely during conversion the cleavage products were dissolved
in 8 M GdmCl for preparative RP-HPLC purification. In this last purification step, it was possi-
ble to eliminate remaining impurities like non-pE-converted Aβ(E3Q-40/42). The purity of
final pEAβ40 and pEAβ42 was checked by analytical RP-HPLC and by Tris/Tricine-
SDS-PAGE [41] and determined to be more than 95% pure (Fig 4a–4c). Final yields of natural
abundant pEAβ40 and pEAβ42 were 15 mg/l culture and 14 mg/l culture, respectively. Yields
for isotope enriched pEAβ were approximately 2 mg/l culture as shown in Table 1.
Biophysical characterization of pEAβ40 and pEAβ42
Formation of amyloid-aggregates of various amyloidogenic proteins can be easily monitored
by the commonly applied ThT assay [42]. Therefore, this assay was used to characterize the
Fig 2. Analytical RP-HPLC of TEV protease cleavage reaction of Aβ(E3Q-40) (a) and Aβ(E3Q-42) (b). The peptides were applied on an analytical
Zorbax SB-300 C8 column and eluted with 30% ACN and 0.1% TFA at 80°C. Black lines indicate analysis after 0.5 h and red lines after 7 h TEV cleavage
reaction at 4°C. Peaks for the fusion proteins decreased while peaks indicating cleaved Aβ(E3Q-40) or Aβ(E3Q-42) were increasing. (c) Semi-preparative
RP-HPLC of TEV-cleaved fusion Aβ(E3Q-40) to separate Aβ(E3Q-40) from remaining fusion protein.
doi:10.1371/journal.pone.0139710.g002
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aggregation kinetics of recombinant pEAβ. Aggregation kinetics of 10 μM solutions of pEAβ40
and pEAβ42 were performed in near-physiological aqueous solution (sodium phosphate
buffer, pH 7.4) at 37°C (Method G in S1 File). Both recombinant pE-modified Aβ peptides
showed the typical properties of Aβ aggregation, i.e. a distinct lag phase, an elongation phase
and a stationary phase over a 12 h incubation period (Fig 5). Compared to pEAβ40, pEAβ42
started to aggregate much faster, already before measurement was started, and reaches its sta-
tionary phase after 4 h. In contrast, at this time point (4 h) pEAβ40 just starts to overcome its
lag phase monitored by ThT assay. Maximum ThT fluorescence intensity for pEAβ40 was
observed after 10 h. The observed different aggregation kinetics of pEAβ40 and pEAβ42 can be
explained by the fact, that the increased C-terminal length in pEAβ42 compared to pEAβ40
but also, in comparison to wild type Aβ(1-40/42) data, N-terminal deletions enhance aggrega-
tion [33, 43].
Fig 3. Non-enzymatic pyroglutamate (pE) formation by acidic and elevated temperature conditions of Aβ(E3Q-40) (a), Aβ(E3Q-42) (b) and wild type
Aβ(3–40) (c). Peptides were incubated at 45°C in sodium acetate buffer pH 3.5 for 24 h. Conversion was observed by analytical RP-HPLC with an analytical
Zorbax SB-300 C8 column in 30% ACN/ 0.1% TFA at 80°C. Peaks for non-modified peptides decreased while peaks for the pEAβ variants appeared at a
longer retention time. (d) Reaction scheme of the conversion of N-terminal E3 or N-terminal Q3 to pE. (e) Mass spectrometry of [U-15N]Aβ(E3Q-40)
compared to N-terminally modified [U-15N]pEAβ40. Molecular mass of the peptides differs in 18 Da due to the loss of the 15NH3 group.
doi:10.1371/journal.pone.0139710.g003
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pEAβ40 and pEAβ42 were further analyzed by solution NMR spectroscopy. 2D and 3D
NMR data were obtained at concentrations varying from 25 to 70 μM in aqueous solution at
pH 7.4 and at 5°C (Method H in S1 File). No changes in chemical shifts could be detected
within three days for pEAβ40 and pEAβ42. The NMR assignments were accomplished using
BEST-TROSY HNCA+ experiments [44] for pEAβ40 and pEAβ42. Fig 6a displays an overlay
of 1H,15N-HSQCs of pEAβ40 compared with the non-converted Aβ(E3Q-40). The loss of two
signals from the γ-amino group due to deamination upon lactam ring formation as well as a
shift of F4 and the appearance of a new signal of the pE3 peptide bond is the main difference.
Fig 4. Analytics of final purified pEAβ. Analytical RP-HPLC of pEAβ40 (a) and pEAβ42 (b) after final purification and corresponding analysis of the
proteins by Tris/Tricine-SDS-PAGE (c). The characteristic RP-HPLC retention times are approximately 9.5 min for pEAβ40 and 15 min for pEAβ42.
doi:10.1371/journal.pone.0139710.g004
Fig 5. ThT assay of 10 μM recombinant pEAβ40 and pEAβ42. Experiments were performed in 10 mM
sodium phosphate buffer pH 7.4 at 37°C. Binding of ThT (10 μM final concentration) to Aβ fibrils was
determined by fluorescence at an extinction of 440 nm and emission at 492 nm.
doi:10.1371/journal.pone.0139710.g005
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The spectra of pEAβ42 showed analogous results, the signals for the N-terminal amino group
and the γ-amino group of Q3 are missing and a signal derived from the intramolecular pE3 lac-
tam group appears (Fig 6b). However, compared with spectra of recombinant Aβ(1–40) and
Aβ(1–42) under similar conditions published previously [45–47], the 1H,15N-HSQC NMR
spectra of pEAβ40 and pEAβ42 differ slightly from Aβ(1-40/42). Although in both pEAβ spe-
cies the N-terminal amino acid pE3 and the neighboring F4 are clearly visible, interestingly, R5
and H6 are missing not only in the pE modified peptides but also in the non-converted mutant
E3Q, maybe due to the histidine-water proton exchange of H6 at neutral pH. Line-broadening
and thus the disappearance of histidine signals were already described [48]. The intermediate
acid-base proton exchange rate as well as the different tautomers of H6 might also affect the
signal of the neighboring residue R5. D7 is shifted to lower frequency but from residue S8 on
till the C-terminus, both NMR spectra for wild type Aβ(1-40/42) and for pEAβ40/42 are nearly
identical.
Conclusion
The described expression and purification system allows, for the first time, reproducible pro-
duction of pEAβ in natural abundance and isotope-enriched in quantities up to 15 mg/l culture
and overcomes the yield and costs limitations to perform reproducible biophysical studies. The
purified pEAβ peptides (pEAβ40 and pEAβ42) showed elevated aggregation kinetics compared
to Aβ(1–40) or Aβ(1–42), but, nonetheless, the monomeric states were suitable for biophysical
studies at 5°C for at least three days. Moreover, it was possible to produce [U-13C,15N] pEAβ40
Fig 6. 1H,15N-HSQC spectra of Aβ(E3Q-40) (blue) and pEAβ40 (red) (a) or of pEAβ42 (b). NMR spectra were recorded from 25 μM protein samples
solved in 10 mM sodium phosphate buffer pH 7.4 at 5°C on a 600 MHz Bruker spectrometer. Note that in (a) “blue” signals derived from Aβ(E3Q-40) are
overlaid with “red” signals from pEAβ40. Therefore “blue” signals are not visible, if identical in shift and intensity to “red” signals.
doi:10.1371/journal.pone.0139710.g006
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and pEAβ42 in high quality and quantity to perform high resolution NMR spectroscopy in
solution state and to assign sequence specific signals of pEAβ40 and pEAβ42 under physiologi-
cal conditions.
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